Skip to main content

The Globe and Mail

Valeant to buy some assets of Austrian company

Valeant Pharmaceuticals International Inc. said it will buy some assets of Austrian pharmaceutical company Gerot Lannach, to boost its presence in Central and Eastern Europe.

These assets of the company, which makes generic branded drugs, generated revenue of about $55 million in 2011.

Under the deal, Valeant will acquire the assets for less than three times sales, with up to an additional $20 million in milestone payments, the company said in a statement.

Story continues below advertisement

Valeant will also enter into a 10-year exclusive supply agreement for the acquired products and will market other Gerot Lannach products in Southeast Asia and Latin America.

The Canadian drug maker has been increasing revenue, mostly through acquisitions, since Biovail Corp., Canada's largest publicly owned pharmaceutical company, took over U.S.-based Valeant and assumed the Valeant name in September, 2010.

Report an error
Comments are closed

We have closed comments on this story for legal reasons. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.